The best Zacks alternative for European and international screening is ScreenerHero; for US-focused earnings-estimate-driven strategies, Zacks itself remains a strong specialist tool. Zacks built its reputation on US earnings estimate revisions and the Zacks Rank — a genuinely useful, well-documented signal for US equities. Its usefulness narrows quickly once you need serious coverage outside the US.
Last updated: July 2026.
What Zacks does well
Zacks' core strength is a specific, well-researched niche: aggregating sell-side analyst earnings estimates and ranking stocks by the direction and magnitude of estimate revisions. The Zacks Rank has genuine academic and practitioner research behind it as a momentum-adjacent signal — estimate revisions tend to correlate with subsequent short-term price performance, and Zacks has built a large business around packaging that signal for retail investors.
For a US large- or mid-cap investor whose strategy is built around earnings estimate momentum, Zacks remains a reasonable, purpose-built tool.
Where Zacks falls short for European and small-cap investors
Earnings estimate data requires analyst coverage — and most of Europe doesn't have it. The entire Zacks Rank methodology depends on multiple sell-side analysts publishing and revising estimates for a stock. European small- and micro-caps, alternative market listings (Euronext Growth, First North, AIM), and thinly covered mid-caps often have one analyst, sporadic coverage, or none at all. The core Zacks signal simply doesn't exist for a large share of the European investable universe.
Screening filters outside the US are limited. Zacks' screener is built around US fundamentals-plus-estimates data. Filtering by operating margin, current ratio, or Debt/EBITDA across a pan-European universe — Germany, France, the Nordics, Iberia, Central and Eastern Europe simultaneously — isn't a workflow the platform is built around.
Pricing is structured around the US estimate-revision product. Zacks Premium and Zacks Investor Collection are priced for the estimate-revision and stock-picking research product specifically, not for broad multi-market fundamental screening.
Zacks vs. alternatives: comparison table
| Feature | Zacks Premium | ScreenerHero (free) | ScreenerHero ($29/mo) |
|---|---|---|---|
| US large/mid cap | ✓ | ✓ | ✓ |
| EU coverage (large cap) | Limited | ✓ | ✓ |
| EU small cap / alt markets | ✗ | ✓ | ✓ |
| Canada | Limited | ✓ | ✓ |
| Earnings estimate revisions | ✓ (core feature) | ✗ | ✗ |
| Fundamental screener filters | Moderate | 30+ | 30+ |
| Account required | Paid | No | No |
| Price | ~$25–50/mo (varies by tier) | Free | $29/mo |
Zacks' estimate-revision data is a genuine differentiator that ScreenerHero doesn't replicate — this is not a claim of feature parity. The comparison is about which tool fits which job: US earnings-momentum research versus broad, multi-market fundamental screening.
Who should still use Zacks
US-focused earnings momentum investors: If your strategy is specifically built around estimate revisions and the Zacks Rank for US large- and mid-cap stocks, Zacks remains a well-established, purpose-built tool for that specific approach.
Investors who want packaged stock picks alongside the data: Zacks' research products bundle analysis and recommendations with the underlying data — useful for investors who want a more guided experience rather than building their own screens.
Who should look elsewhere
European and international investors: If your universe includes European small-, mid-, or micro-caps — or Canadian markets — Zacks' US-centric estimate model and screening depth won't cover a meaningful share of your investable universe.
Investors building fundamental, not estimate-based, screens: If your process is built around balance sheet quality, valuation multiples, and profitability metrics rather than analyst estimate momentum, a broader fundamental screener is a better fit regardless of geography.
Bottom line
Zacks is a well-built specialist tool for a specific strategy — US earnings estimate revision momentum — and remains a reasonable choice for investors whose process depends specifically on that signal. It is not built for broad European or small-cap fundamental screening, largely because its core methodology depends on analyst coverage that doesn't exist for most of the European small-cap universe. For multi-market fundamental screening across the US, Canada, and all of Europe, a broader tool built around reported financials rather than analyst estimates is the better fit.
Frequently asked questions
Does Zacks cover European stocks?
Zacks has limited coverage of European stocks, and its core estimate-revision methodology is weakest exactly where European small- and mid-cap coverage is thinnest — because the Zacks Rank depends on multiple analysts publishing and revising earnings estimates, which many European companies outside the largest names simply don't have.
Is the Zacks Rank useful for European stocks?
Rarely, in practice. The Zacks Rank is built on the volume and direction of analyst estimate revisions, and most European small- and mid-cap stocks have too little consistent analyst coverage for the signal to be meaningfully calculated or reliable.
What's a good Zacks alternative for screening European small caps?
ScreenerHero covers European small-, mid-, and micro-cap markets — including alternative exchanges like Euronext Growth, First North, and AIM — with fundamental screening filters built around reported financials rather than analyst estimates, which is a better fit for markets with thin or absent analyst coverage.
Screen European, US, and Canadian stocks → — free, no account required. Filter by fundamentals across all major exchanges, including markets with limited analyst coverage.